Outsourcing

ADC Bio experts warn of impending problems in the ADC pipeline with millions wasted in development costs.

Alcami will manufacture clinical supply of the API for a drug candidate targeting various hematologics and solid cancers.

The companies have established a joint laboratory to develop full continuous processing to manufacture high yields of monoclonal antibodies at reduced costs.

The company has officially opened a local brand office in South Korean to support its existing business in the region.

Almac Group will acquire BioClin Laboratories to expand Almac’s analytical service offerings.

Recent acquisitions are creating CDMOs with scale that rivals global bio/pharma.

The M&A advisory firm has developed an interactive map of manufacturing sites to give insight into the market size of global manufacturing.

ABEC, an equipment and engineering company, will provide a custom-made, single-use bioreactor to custom manufacturing firm, Emergent, for its Maryland manufacturing facility.

The API manufacturer has announced that it has completed the expansion of large-scale manufacturing capabilities at its Charles City, Iowa site.

Samsung BioLogics’ second facility adds 152,000 L of mAb drug substance capacity.

The collaboration will focus on developing a novel and differentiated challenge model for respiratory syncytial virus.

CordenPharma will integrate the Hospira Boulder API manufacturing facility into the CordenPharma Colorado network for highly potent and oncology APIs.

Hitachi Chemical Advanced Therapeutics Solutions will expand its PCT service platform for cell therapy by adding GMP manufacturing and cleanroom capacity in Allendale, NJ.

Groninger will showcase its FlexPro 50 line for small batch production at CPhI Worldwide 2017, and present on up- and downstream processes with freeze-dryer developer and manufacturer Martin Christ.

Detecting viral contaminants in biologic-based medicines-and identifying their source-requires a holistic testing approach.

Mergers and acquisitions are positive for the CDMO industry, but there is a downside.

KBI Biopharma, a biopharmaceutical contract development and manufacturing organization, will manufacture an antibody and a fusion protein developed by Heat Biologics’ subsidiary.

Fresenius Kabi broke ground on a previously announced $250 million expansion of its Melrose Park, IL, manufacturing facility.

ADC Bio announces plans to expand into clinical and commercial drug manufacturing for ADCs.

Ajinomoto Althea opens manufacturing suites in new high potency and antibody drug conjugate commercial facility.

The acquisition adds to Catalent’s capabilities in biologics development, analytical services, manufacturing, and finished product supply.

Innovation speeds discovery, drives down costs, and improves productivity.

Despite some progress, the industry is still in a wait-and-see mode regarding the administration, Congress, and FDA.

Catalent Applied Drug Delivery Institute announced a partnership with Rutgers University to examine the challenges of pediatric drug formulation and delivery.

Contract manufacturers await a promising pipeline of drug products to jump-start stagnant growth.